

ELEVATE

ADVANCING SCIENCE IN MBC

EDUCATION

EVIDENCE

EXPERIENCE

PROGRAMME BOOKLET


Personalising treatment for MBC patients:

Finding the right path



25–26 October 2024

Crowne Plaza Brussels Airport, Brussels, Belgium



 **Pfizer**
Oncology

Welcome!

Dear colleagues,

It is our great pleasure to welcome you to the live ELEVATE meeting “Personalising treatment for MBC patients: Finding the right path” at the Crowne Plaza Brussels Airport, Brussels, Belgium, and to welcome all colleagues who are joining the event virtually from around the world.

ELEVATE has been established as a platform for expert faculty to share their clinical experience in MBC. Underpinned by the three core pillars of Education, Evidence and Experience, ELEVATE provides an educational and interactive forum for HCPs from across the globe to discuss key topics at the forefront of MBC management and exchange experience.

This meeting will provide an interactive forum for breast oncologists to discuss important topics in MBC management and deep dive into clinical data and recent updates on real-world evidence in MBC, as well as providing an opportunity to look to the future of the MBC treatment landscape. In addition to plenary sessions, there will be panel discussions, interactive workshops and we will also hear the patient’s perspective throughout the meeting.

The meeting will also provide you with an opportunity to interact closely with widely respected experts and peers, and to share knowledge, experience and insights.

We hope you find this meeting truly informative and valuable!



**Professor
Massimo Cristofanilli**

Professor of Medicine & Director
of Breast Medical Oncology at
Weill Cornell Medicine,
New York, USA



**Professor
Paul Cottu**


Professor of Medicine &
Head of Day Care Unit, Department
of Medical Oncology, Institut Curie,
Paris, France



Table of contents

	Welcome	1
	Venue map	3
	Meeting agenda day 1	5
	Meeting agenda day 2	6
	Chair and speaker biographies	
	Chair biographies	
	Professor Massimo Cristofanilli	7
	Professor Paul Cottu	8
	Speaker biographies	
	Dr Tanja Španić	9
	Associate Professor Assia Konsoulova	10
	Dr Rodrigo Dienstmann	11
	Professor Giuseppe Curigliano	12
	Professor Marc Thill	13
	Dr Javier Pascual	14
	Dr Luca Malorni	15
	Live Q&A, polling & evaluation form	16
	Logistics & key contacts	17
	Learn more about Brussels!	18


Venue map




Park level





-  Purple breakout room – Botanique/Warande
-  Pink breakout room – Egmont/Leopold/Soignes

Ground floor



-   Green breakout room/Plenary room - Merode
-  Lunch



-  Blue breakout room - Craft Private Dining Room
Please note: the 'Craft Private Dining Room' is located off the hotel lobby area on the ground floor, next to the restaurant.

Day 1: Friday 25th October

Meeting agenda

12:30–13:30 *Lunch held in Pre-Function Merode*

13:30 **Welcome to ELEVATE 2024!**
Massimo Cristofanilli & Paul Cottu

13:35 **Chairs' introduction**
Massimo Cristofanilli & Paul Cottu

13:45 **Collaboration throughout the MBC treatment journey:
Considering the patient & HCP perspective**
Tanja Španić & Assia Konsoulova

14:10 **RWE: Thoughts from the Chair**
Paul Cottu

14:15 **The totality of evidence supporting MBC treatment decisions: Understanding RWE**
Rodrigo Dienstmann

14:30 **Q&A session**
Rodrigo Dienstmann, Tanja Španić & Assia Konsoulova, moderated by Paul Cottu

14:40 **Selecting a 1L treatment for the HR+ HER2- patient**
Massimo Cristofanilli & Paul Cottu

15:00 **Q&A session**
Paul Cottu, Giuseppe Curigliano & Rodrigo Dienstmann,
moderated by Massimo Cristofanilli

15:15 *Break*

15:30 **Workshop rotation 1**

1 **Implementing RWE:
Breaking down the barriers**
Rodrigo Dienstmann & Paul Cottu

2 **Clinical spotlight:
HR+ HER2- MBC patient case**
Massimo Cristofanilli & Assia Konsoulova

3 **Clinical spotlight:
HER2+ MBC patient case**
Giuseppe Curigliano & Marc Thill

4 **Biomarker-based
treatment decisions**
Luca Malorni & Javier Pascual

16:20 **Transition time**

16:25 **Workshop rotation 2**

17:15 **Transition time**

17:20 **Selecting a 2L+ treatment for the HR+ HER2- patient**
Marc Thill & Assia Konsoulova

17:40 **Q&A session**
Marc Thill, Assia Konsoulova, Giuseppe Curigliano & Rodrigo Dienstmann,
moderated by Paul Cottu

17:55 **ESMO President Elect: Discussion with Professor Giuseppe Curigliano**
Giuseppe Curigliano, moderated by Massimo Cristofanilli

18:05 **Chairs' close of Day 1**
Massimo Cristofanilli & Paul Cottu

18:10 **Group photo, networking & dinner**

Day 2: Saturday 26th October

Meeting agenda

08:30 **Welcome back**
Massimo Cristofanilli & Paul Cottu

08:35 **HER2+ MBC: A rapidly evolving treatment landscape**
Giuseppe Curigliano & Marc Thill

09:05 **Q&A session**
Giuseppe Curigliano & Marc Thill, moderated by Paul Cottu

09:15 **Hot topics: Looking to the future, how will the MBC treatment landscape evolve?**
Javier Pascual, Luca Malorni & Giuseppe Curigliano,
moderated by Massimo Cristofanilli & Paul Cottu

09:50 *Break*

10:10 **Workshop rotation 3**

11:00 **Transition time**

11:05 **Workshop rotation 4**

11:55 **Transition time**

12:00 **Looking to the future: Harnessing the power of MBC patient data with AI**
Rodrigo Dienstmann & Javier Pascual

12:25 **Q&A session**
Rodrigo Dienstmann & Javier Pascual, moderated by Massimo Cristofanilli

12:40 **Interactive MBC trivia challenge**
Massimo Cristofanilli & Paul Cottu

12:50 **Chairs' closing remarks**
Massimo Cristofanilli & Paul Cottu

13:00 **End of meeting and departures**

'To-go' lunch boxes are available from 13:00

Chair and speaker biographies

Chair biographies



**Professor
Massimo Cristofanilli**

Massimo Cristofanilli, MD, FACP, is a board-certified medical oncologist with more than two decades of experience as a physician, investigator and researcher. In 2022, he joined Weill Cornell Medicine/NewYork-Presbyterian as a professor of medicine, chief of Breast Medical Oncology, and associate director of Precision Medicine at the Meyer Cancer Center. He is also scientific director of the Englander Institute of Precision Medicine. Professor Cristofanilli has an extensive background in clinical trial design for metastatic and locally advanced breast cancer, collaborating with industry partners on trials submitted for regulatory approval – for example, the PALOMA-3 study. He is a standing member of the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration and is co-founder and past president of the International Society of Liquid Biopsy. Pioneering clinical testing of circulating tumour cells (CTCs) in MBC, Professor Cristofanilli led a multicentre study that was the first to demonstrate the prognostic value of liquid biopsy in solid tumours. His laboratory continues to investigate the development and clinical application of circulating tumour DNA and CTC technologies, from early detection and screening to measurable residual disease monitoring and molecular assessment of advanced breast cancer.



**Professor
Paul Cottu**

Paul Cottu, MD, PhD, is currently head of the day care unit in the Department of Medical Oncology at Institut Curie in Paris and an Associate Professor of Oncology at Université Paris Cité. After graduating from Université Paris Cité in 1995 with a degree in medical oncology, he undertook a fellowship in the Department of Health Care Policy at Harvard Medical School in Boston. His research is focused on resistance to endocrine therapy and the role of neoadjuvant therapy in luminal breast cancer. Professor Cottu also develops research on real-world cohorts in both early and advanced breast cancer. He has published more than 250 peer-reviewed articles and currently serves as co-chair of the international RIBOLARIS trial. He is a member of the bureau of the Unicancer Breast Cancer Group.

Speaker biographies



Dr Tanja Španić

Tanja Španić, DVM, PhD, has a professional background in veterinary medicine and a PhD in molecular and behavioural neuroscience. She is a professional patient advocate and current president of Europa Donna Slovenia and past president of Europa Donna – The European Breast Cancer Coalition. Dr Španić was diagnosed with breast cancer at the age of 26. A year after her diagnosis, she joined Europa Donna Slovenia. Since then, she has been an active breast cancer advocate, both nationally and internationally.

Currently Dr Španić has active roles as a faculty member for Breast Cancer in Young Women (BCY) and the European Breast Cancer Conference (EBCC); as a steering committee member of the OlympiA and POSITIVE clinical trials; as chair of the European Society for Medical Oncology (ESMO) Patient Advocates Working Group and member of the ESMO policy-making group; as a member of the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) in Oxford, UK; and for The *Lancet* Breast Cancer Commission team. In Slovenia, Dr Španić is a member of the ethics committee at the Institute of Oncology, the steering committee for screening programmes at the Ministry of Health, and the health council at the Ministry of Health. She is the co-author of several scientific papers on breast cancer.




**Associate Professor
Assia Konsoulova**

Assia Konsoulova is head of the Medical Oncology Clinic at the National Cancer Institute, Sofia, Bulgaria. She is also founder and member of the board of the Bulgarian Joint Cancer Network (BJCN), and head of the cluster sector on comprehensive oncology centres, networking, and innovation. Her professional career includes specialisations at international cancer centres, including the Jules Bordet Institute, Brussels, Belgium; Vienna General Hospital (AKH), Vienna, Austria; and Champalimaud Clinical Cancer Centre, Lisbon, Portugal.

Dr Konsoulova is a holder of national and international honours such as the national MORE-Darzas award for most significant input into Bulgarian clinical oncology in 2016 and most trusted Bulgarian physician for 2021, 2023, and 2024. She is an auditor for the Accreditation and Designation Programme of the Organisation of European Cancer Institutes (OECI), Bulgarian ambassador for the European School of Oncology (ESO), and a graduate of the College of the European School of Oncology (ESCO). Dr Konsoulova is also a member of the European Society for Medical Oncology (ESMO) and American Society of Clinical Oncology (ASCO), chair of Women for Oncology – Bulgaria, member of the Global Alliance, and a member of the ethics committee of the Society of Young Oncologists in Bulgaria.

Speaker biographies



**Dr Rodrigo
Dienstmann**

Rodrigo Dienstmann, MD, is a medical oncologist, group leader of the Oncology Data Science Group at Vall d'Hebron Institute of Oncology in Barcelona, Spain, and head of genomics at Oncoclínicas OC Precision Medicine, Oncoclínicas & Co, São Paulo, Brazil. He is also editor-in-chief of *ESMO Real-World Data and Digital Oncology*. His postgraduate work included work in early clinical trials at Vall d'Hebron Institute of Oncology; in molecular pathology at Massachusetts General Hospital in Boston, MA, USA; and in data science at Sage Bionetworks in Seattle, WA, USA.



**Professor
Giuseppe Curigliano**

Giuseppe Curigliano, MD, PhD, is director of the Early Drug Development Division and co-chair of the Experimental Therapeutics Program at the European Institute of Oncology, a comprehensive cancer centre in Milan, Italy. He is a steering committee member in the Department of Oncology and Hematology-Oncology at the University of Milan, and a member of the Italian National Health Council. He is a past member of the expert panel issuing the AIOM, ESMO, and ASCO guidelines in breast cancer and germline gene testing recommendations. He is principal investigator and a steering committee member for numerous clinical trials, particularly with innovative targeted compounds and individualised treatment strategies. His translational research focusses on the field of biomarkers and personalised therapies. Professor Curigliano has authored more than 670 papers in peer-reviewed journals and many book chapters, and has served as an editorial board member for international journals in oncology. He is a panel member of several international breast cancer consensus conferences and is currently editor-in-chief of *ESMO Open* and the president-elect of ESMO.

Speaker biographies



**Professor
Marc Thill**

Marc Thill is director of the Department of Gynaecology and Gynaecologic Oncology and spokesperson of the Interdisciplinary Breast Cancer Centre and the Oncological Centre at the Agaplesion Markus Hospital in Frankfurt, Germany. He specialises in gynaecological oncology and is a certified breast surgeon and gynaecological reconstructive surgeon. His scientific focus is on surgical and systemic treatment of breast cancer. He is chairman of the board of directors of the German Association of Aesthetic, Plastic, and Reconstructive Surgery in Gynaecology and a member of several scientific boards and groups, including the scientific sub-board of the German Breast Group, the breast cancer guideline committee of the German Association of Gynaecological Oncology, the German S3 guideline committee, and the German Society of Gynaecology and Obstetrics. Professor Thill is the author or co-author of 202 original and review articles, 10 book chapters, one book, and 187 citable presentations, and has given more than 1000 national and international talks.



Dr Javier Pascual

Javier Pascual, MD, is a medical oncologist specialising in breast cancer. He graduated from the University of Seville, Spain, with a degree in medicine and earned a master's degree from the University of Girona, Spain, and a Doctor of Medicine degree from the Institute of Cancer Research at the University of London, UK. He currently works as a clinician scientist in the University Hospital Virgen de la Victoria and the Malaga Biomedical Research Institute, Spain, where he combines clinical duties (mainly treating patients with breast cancer), coordination of the breast cancer clinical trial programme, research activities as principal investigator of the Translational Liquid Biopsies Laboratory, and institutional work as scientific director of the Cancer Molecular Biology Laboratory. His main interests are the treatment of patients with breast cancer based on tumour biology, especially in the context of clinical trials, and the use of new techniques for detection of molecular alterations (mainly through liquid biopsies in plasma) for clinical decision making in cancer care.

Speaker biographies



Dr Luca Malorni


Luca Malorni, MD, PhD, is a medical oncologist and translational researcher, currently serving as director of the Translational Research Unit at Hospital Santo Stefano of Prato, Department of Oncology, Azienda USL Toscana Centro, Prato, Italy. He was trained at the University of Naples Federico II, Naples, Italy, where he earned his MD and PhD degrees. He is a former postdoctoral fellow (2006–2010) of the Lester and Sue Smith Breast Center, and a faculty member of the Department of Medicine, both at Baylor College of Medicine, Houston, TX, USA, where he held the position of adjunct Clinical Assistant Professor from 2010 to 2017. Dr Malorni's principal research interest is the study of mechanisms and biomarkers of resistance to endocrine and targeted therapies in breast cancer. He has extensive expertise in preclinical and translational research, and longstanding experience as a principal investigator in clinical trials with a strong translational research component (TREN: NCT02549430; IBCSG 53-14/BIG 14-04 – PYTHIA: NCT02536742; IBCSG 55-17 – TOUCH: NCT03644186; TIRESIAS: NCT04660435). He has received research grants from national and international organisations (Fondazione AIRC: IG-22869 and MFAG 18880; Pfizer; Novartis).

Dr Malorni has authored more than 60 publications and has regularly presented original data at international meetings (ASCO, San Antonio Breast Cancer Symposium, ESMO, ESMO Breast Cancer). Additionally, he has served as a scientific committee member for several international conferences (ESMO 2022, European Breast Cancer Conference [EBCC-13 and EBCC-12], IMPAKT Breast Cancer Conference 2014 and 2015).


Have your say!



You can join in with the ELEVATE meeting using the **Slido** interactive voting system. Please scan the QR code with your phone to connect.



Once you are connected to Slido, please select the room you are in. You will then be able to respond to the **audience polls** and **ask questions** to the faculty.



Before the meeting starts, please fill out the **pre-meeting survey**.

At the end of Day 1 and Day 2, please fill out the **post-meeting evaluation surveys**.

Logistics and key contacts

Contact

Key meeting contact:

Kelley Ruff +1 678 468 9208

Hotel

Address

Crowne Plaza Brussels Airport,
Da Vincilaan 4, 1831 Brussels,
Belgium

Telephone number

+32 2 416 33 33

Check-in time

15:00

Check-out time

12:00

Breakfast

Available from 06:00–10:00, held in the hotel restaurant

Lunch

Friday: 12:30–13:30, held in Pre-Function Merode
Saturday: 'To-go' lunch boxes, available from 13:00



Networking dinner

Join us for a networking dinner on Friday 25th October at 19:30, held in the Solvay Library. Please meet in the hotel lobby at 18:45

Departures:

Airport transfer pick up will be 3 hours prior to your flight departure time detailed in your itinerary. If you have any questions, please contact a member of staff at the registration desk. Alternatively, there is a hotel shuttle service every 20 minutes from 06:00 to 22:40.

Taxi

Taxis Bleus

+32 (0)2 268 00 00

Taxis Verts

+32 (0)2 349 49 49

Taxi Victor Cab

+32 (0)2 425 25 25

Emergency number (emergency services, ambulance, police and fire brigade):

100 (Belgium) or 112


Non-urgent medical assistance

(for any health queries):

1733

Learn more about Brussels!

Welcome to Brussels! Here are some popular places to visit in your downtime:



Suggested places to visit:



Royal Palace of Brussels: Palace of the constitutional monarchy surrounded by a royal park on site with statues, a fountain and outdoor theatres

~20 minutes



Josaphat Park: Park with ponds, trails and sculptures

~20 minutes



Mount of the Arts: Museum and parks

~25 minutes



Grand Place: City square encircled by elegant historic buildings dating back to the 14th century

~30 minutes

Restaurants

Anton Pieck (Belgian/European)
<https://www.antonpieck.be/>

Antonio Morreale (Italian/French)
<https://www.antoniomorreale.be/>

Make sure to also try traditional **Belgian waffles!**

This meeting is organised and funded by Pfizer.
©2024 Pfizer Inc. All rights reserved.
Date of preparation: October 2024. PP-IBR-GLB-1394
www.pfizer.com

